Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:INNT

Innovate Biopharmaceuticals (INNT) Stock Price, News & Analysis

Innovate Biopharmaceuticals logo

About Innovate Biopharmaceuticals Stock (NASDAQ:INNT)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.56
$1.42
52-Week Range
N/A
Volume
25 shs
Average Volume
525,982 shs
Market Capitalization
$8 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive INNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Innovate Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

INNT Stock News Headlines

This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.
See More Headlines

INNT Stock Analysis - Frequently Asked Questions

Innovate Biopharmaceuticals Inc (NASDAQ:INNT) issued its quarterly earnings data on Monday, March, 18th. The company reported ($0.11) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.11).

Based on aggregate information from My MarketBeat watchlists, some other companies that Innovate Biopharmaceuticals investors own include 9 Meters Biopharma (NMTR), NIO (NIO), Corbus Pharmaceuticals (CRBP), Energy Transfer (ET), Iterum Therapeutics (ITRM), Meta Platforms (META) and Micron Technology (MU).

Company Calendar

Last Earnings
3/18/2019
Today
7/05/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:INNT
Fax
N/A
Employees
8
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$27.05 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
($0.27) per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$8 thousand
Optionable
Not Optionable
Beta
-0.39
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (NASDAQ:INNT) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners